Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein–Enriched Serum in Rheumatoid Arthritis

Keyphrases

• Adalimumab 27%
• Cellular Cholesterol 9%
• Cholesterol Efflux Capacity 100%
• Clinical Information 9%
• Coronary Artery Disease 9%
• Coronary Risk Factors 9%
• Disease Activity 18%
• Disease Activity Score 28 (DAS28) 27%
• Drug Effects 100%
• Drug Therapy 100%
• Erythrocyte Sedimentation Rate 27%
• Fluorometric Assay 9%
• High Density 100%
• High-density Lipoprotein Cholesterol (HDL-C) 36%
• Inflammation 18%
• Methotrexate 27%
• New Drugs 9%
• Non-rheumatoid 9%
• Paired Serum 9%
• Rheumatoid Arthritis 100%
• Rheumatoid Arthritis Treatment 27%
• Serum Samples 18%
• Starting Treatment 9%
• THP-1 Macrophages 9%
• Tocilizumab 36%
• Treatment Efficacy 9%
• Treatment Toxicity 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Adalimumab 27%
• Combination Therapy 9%
• Disease Activity 18%
• Disease Activity Score 27%
• Effusion 100%
• High Density Lipoprotein 27%
• High Density Lipoprotein Cholesterol 9%
• Inflammation 18%
• Ischemic Heart Disease 18%
• Methotrexate 27%
• Pharmacotherapy 100%
• Rheumatoid Arthritis 100%
• Tocilizumab 36%

Immunology and Microbiology

• Adalimumab 33%
• Erythrocyte Sedimentation Rate 33%
• Inflammatory Arthritis 100%
• Macrophage 11%
• Methotrexate 33%
• Tocilizumab 44%